The patients were treated with Betaferon, Rebif, and Avonex (45%, 39%, and 12%, respectively); all 3 medications are different brands of the beta 1-a class of interferons commonly used in the treatment of MS. The gene discussed is PSMB6; the disease is myeloid sarcoma.